4basebio (XTER:88Q) Debt-to-Asset : 0.00 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is 4basebio Debt-to-Asset?

4basebio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €0.00 Mil. 4basebio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €0.00 Mil. 4basebio's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2023 was €13.47 Mil. 4basebio's debt to asset for the quarter that ended in Jun. 2023 was 0.00.

4basebio Debt-to-Asset Historical Data

The historical data trend for 4basebio's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4basebio Debt-to-Asset Chart

4basebio Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Debt-to-Asset

2.24

0.10

0.12

0.29

4basebio Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Debt-to-Asset	Get a 7-Day Free Trial			-	0.12	-	0.29	-

Competitive Comparison of 4basebio's Debt-to-Asset

For the Biotechnology subindustry, 4basebio's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

4basebio's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4basebio's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where 4basebio's Debt-to-Asset falls into.

4basebio Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

4basebio's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.477	+	3.375)	/	13.44
	=	0.29

4basebio's Debt-to-Asset for the quarter that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	13.467
	=	0.00

4basebio (XTER:88Q) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

4basebio Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of 4basebio's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

4basebio (XTER:88Q) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4basebio PLC (XTER:88Q) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

4BB:UK

Address

25 Norman Way, Over, Cambridge, GBR, CB24 5QE

Website

https://www.4basebio.com

4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for the effective and safe delivery of these DNA-based products to patients. Its country of operation is the UK. It is engaged in the manufacturing and supply of high-purity, synthetic DNA for research, therapeutic and pharmacological use.

4basebio (XTER:88Q) Headlines

No Headlines